NCT04531982Phase 3Completed

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-01-25Actual
Enrollment · participants454Actual
Source updated2025-08-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview